

## Curriculum Vitae

Personal information **Jaana Palomäki**

### Work experience

---

1. Employer: Finnish Medicines Agency Fimea
  - Start date: 09/2022
  - End date: (ongoing)
  - Position: Senior Researcher
  - Activities: Non-clinical assessment of medicinal products; Environmental risk assessment; Scientific advice for the development of medicinal products; Non-clinical assessment of clinical trial applications
  - Country: Finland
2. Employer: DRA Consulting Oy
  - Start date: 01/2021
  - End date: 08/2022
  - Position: Senior Adviser, Pharmacovigilance and Medical Info Team Lead
  - Activities: Consultation of pharmaceutical and medical device companies: Pharmacovigilance tasks, such as acting as EU-QPPV; medical writing (e.g., clinical dossier preparation); tasks related to MDR 2017/745 technical documentation (e.g., risk management plan, B/R evaluation, biological safety evaluation).
  - Country: Finland
3. Employer: Santen Oy
  - Start date: 03/2018
  - End date: 01/2021
  - Position: Specialist, Safety Vigilance
  - Activities: Risk management including RMPs, authoring PSURs, signal management & safety management in clinical trials
  - Country: Finland
4. Employer: Finnish Safety and Chemicals Agency TUKES
  - Start date: 08/2013
  - End date: 03/2018
  - Position: Senior Officer
  - Activities: EU Biocides Regulation (528/2012): Human health hazard and risk assessment of biocidal substances and products, Hazard and risk assessment of active substances, Risk assessment and characterization of biocidal products, ECHA Committee work such as biocides human health WG and Endocrine Disruptor (ED) EG memberships
  - Country: Finland
5. Employer: Finnish Institute of Occupational Health FIOH
  - Start date: 06/2008
  - End date: 12/2013
  - Position: Researcher
  - Activities: Evaluation of toxicological and immunological effects induced by engineered nanomaterials in different lung cell types *in vitro*, mouse atopic dermatitis model *in vivo* and mechanisms behind observed phenomena. Methods routinely used in the analysis were e.g., RT-PCR, ELISA, Luminex, flow cytometry, immunohistochemistry and proteomics assays (2-DE, DIGE -labeling, mass spectrometry).
  - Country: Finland

### Education and training

---

1. Subject: Nanotoxicology, immunotoxicology
  - Start date: 10/2009
  - End date: 01/2015
  - Qualification: Ph.D. Toxicology
  - Organisation: University of Helsinki
  - Country: Finland
2. Subject: General toxicology
  - Start date: 08/2005
  - End date: 09/2009
  - Qualification: M.Sc. Toxicology
  - Organisation: University of Eastern Finland
  - Country: Finland
3. Subject: Pharmaceuticals
  - Start date: 08/2002
  - End date: 05/2005
  - Qualification: B.Sc. Pharmacy
  - Organisation: University of Eastern Finland
  - Country: Finland

### Additional information

---

#### Publications

Palomäki J, Sund J, Vippola M, Kinaret P, Greco D, Savolainen K, Puustinen A, Alenius H. A secretomics analysis reveals major differences in the macrophage responses towards different types of carbon nanotubes. *Nanotoxicology*

2015;9(6):719\_28. doi: 10.3109/17435390.2014.969346

Palomäki J, Välimäki E, Sund J, Vippola M, Clausen PA, Jensen KA, Savolainen K, Matikainen S, Alenius H. Long, needle\_like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. *ACS Nano* 2011;5(9):6861\_70. doi: 10.1021/nn200595c

Palomäki J, Karisola P, Pyökkänen L, Savolainen K, Alenius H. Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells. *Toxicology* 2010;267(1\_3):125\_31. doi: 10.1016/j.tox.2009.10.034.

Neubauer N, Palomäki J, Karisola P, Alenius H, Kasper G. Size\_dependent ROS production by palladium and nickel nanoparticles in cellular and acellular environments – An indication for the catalytic nature of their interactions. *Nanotoxicology* 2015 (8): 1059\_1066. doi: 10.3109/17435390.2015.1019585

Ilves M, Palomäki J, Vippola M, Lehto M, Savolainen K, Savinko T, Alenius H. Topically applied ZnO nanoparticles suppress allergen induced skin inflammation but induce vigorous IgE production in the atopic dermatitis mouse model. *Part Fibre Toxicol.* 2014;11:38. doi: 10.1186/s12989\_014\_0038\_4.

Sund J, Palomäki J, Ahonen N, Savolainen K, Alenius H, Puustinen A. Phagocytosis of nano\_sized titanium dioxide triggers changes in protein acetylation. *J Proteomics* 2014;108:469\_83. doi: 10.1016/j.jprot.2014.06.011

Koivisto AJ, Palomäki JE, Viitanen AK, Siivola KM, Koponen IK, Yu M, Kanerva TS, Norppa H, Alenius HT, Hussein T, Savolainen KM, Hämeri KJ. Range\_finding risk assessment of inhalation exposure to nanodiamonds in a laboratory environment. *J Environ Res Public Health* 2014;11(5):5382\_402. doi: 10.3390/ijerph110505382.

Ågerstrand M, Christiansen S, Hanberg A3, Rudén C, Andersson L, Andersen S, Appelgren H, Bjørge C, Clausen IH, Eide DM, Hartmann NB, Husøy T, Halldórsson HP, van der Hagen M, Ingre\_Khans E, Lillicrap AD, Beltoft VM, Mörk AK, Murtomaa\_Hautala M, Nielsen E, Ólafsdóttir K, Palomäki J, Papponen H, Reiler EM, Stockmann\_Juvala H, Suutari T, Tyle H, Beronius A. A call for action: Improve reporting of research studies to increase the scientific basis for regulatory decision\_making. *J Appl Toxicol.* 2018;38(5):783\_785. doi: 10.1002/jat.3578.

Kankkunen P, Välimäki E, Rintahaka J, Palomäki J, Nyman T, Alenius H, Wolff H, Matikainen S. Trichothecene mycotoxins activate NLRP3 inflammasome through a P2X7 receptor and Src tyrosine kinase dependent pathway. *Hum Immunol.* 2014;75(2):134\_40. doi: 10.1016/j.humimm.2013.11.010.

Book Chapter: Nanomaterials and Human Health. *Handbook of Nanosafety: Measurement, Exposure and Toxicology*, 2014

Doctoral dissertation (article\_based): Immunotoxicological effects induced by engineered nanomaterials, 2014, Helsinki University Print. <https://helda.helsinki.fi/handle/10138/136095>

## Projects

## Memberships

## Other Relevant Information